You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial

Citation Tools

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shaw H, Patel P, Payne M, et al
1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1533